GURU.Markets stock price, segment price, and overall market index valuation
The company's share price XORTX Therapeutics Inc.
XORTX is a biotech company developing drugs for the treatment of kidney disease and gout by targeting uric acid metabolism. Its stock price is highly volatile, as the company's value is determined not by current revenue, but by news about the progress of clinical trials of its key candidates for the treatment of polycystic kidney disease and gout.
Share prices of companies in the market segment - Pharma immune
XORTX Therapeutics is a pharmaceutical company developing drugs for the treatment of kidney diseases, particularly those associated with abnormal uric acid metabolism. We have classified it in the Pharma: Immunology segment. The chart below shows the dynamics in the nephrology sector.
Broad Market Index - GURU.Markets
XORTX Therapeutics is a Canadian biopharmaceutical company developing drugs for the treatment of kidney diseases. It is a component of the GURU.Markets index. The chart below shows the US market. See how this company's stock compares to the US market trend.
Change in the price of a company, segment, and market as a whole per day
XRTX - Daily change in the company's share price XORTX Therapeutics Inc.
For XORTX Therapeutics Inc., which develops drugs to treat kidney disease, daily volatility reflects sensitivity to clinical trial data. This metric is an important element in risk assessment.
Daily change in the price of a set of shares in a market segment - Pharma immune
XORTX Therapeutics develops drugs for the treatment of kidney and cardiovascular diseases by targeting uric acid metabolism. This is a highly specialized area of pharmaceuticals. The chart below shows the average volatility in this sector, allowing you to assess the performance of XRTX shares.
Daily change in the price of a broad market stock, index - GURU.Markets
XORTX Therapeutics is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization XORTX Therapeutics Inc.
XORTX Therapeutics Inc.'s year-over-year performance is a story of kidney disease drug development. Its 12-month market cap is entirely dependent on clinical trial data. Success of its lead candidate, which targets uric acid levels, could offer a new approach to treating polycystic kidney disease.
Annual dynamics of market capitalization of the market segment - Pharma immune
XORTX, a late-stage biotech company, is developing drugs for the treatment of kidney diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
XORTX Therapeutics is a classic biotech company whose fate is decided in the lab. Its year-over-year performance compared to the S&P 500 tells a story not about economics but about investors' faith in the success of its kidney disease drugs. Any news of progress or setback can send the stock plummeting or plummeting.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization XORTX Therapeutics Inc.
XORTX is a biopharmaceutical company focused on kidney diseases. Its monthly performance is entirely dependent on progress in its clinical programs. News of its lead drug's trial results is the primary driver.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Biotech companies working in kidney and metabolic diseases are solving complex medical problems. The dynamics of this sector, shown in the graph, reflect the high risks of R&D. In this environment, companies like XORTX Therapeutics are pursuing their clinical programs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
XORTX, a biopharmaceutical company developing drugs to treat kidney disease, lives by the laws of science. Its shares are driven by news of trials, and their performance is completely disconnected from overall economic trends, which is typical for biotech.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization XORTX Therapeutics Inc.
XORTX Therapeutics develops drugs to treat kidney diseases, including those associated with COVID-19. Its weekly stock price reflects news of clinical trials and general scientific interest in its approach to treating progressive kidney disease.
Weekly dynamics of market capitalization of the market segment - Pharma immune
XORTX Therapeutics develops drugs to treat kidney diseases linked to abnormal uric acid metabolism. This is a new approach to a well-known problem. The chart shows how much the company's stock price is driven by internal news rather than general trends in nephrology.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
XORTX Therapeutics develops drugs for the treatment of kidney diseases. Its shares are steeped in clinical trials and scientific data. The chart shows how its performance depends solely on internal news, rather than on overall market movements.
Market capitalization of the company, segment and market as a whole
XRTX - Market capitalization of the company XORTX Therapeutics Inc.
XORTX Therapeutics' market capitalization reflects investors' bets on its novel approach to treating kidney disease. The chart shows the market's belief that by lowering uric acid levels, its drugs will slow the progression of kidney failure. Its low price reflects both the potential of its theory and the high risk of clinical trials.
XRTX - Share of the company's market capitalization XORTX Therapeutics Inc. within the market segment - Pharma immune
XORTX Therapeutics is a Canadian biopharmaceutical company developing drugs to treat kidney disease. Its market share is small, but it is based on a unique approach. Its market cap is based on its therapy, which aims to lower uric acid levels to slow the progression of the disease.
Market capitalization of the market segment - Pharma immune
This chart shows the overall value of the entire biotech sector specializing in immune therapy. For XORTX, a stock in this field, this line is a map of the future of medicine. The chart's rise reflects investors' belief that modulating the immune system is key to treating the most complex diseases, from cancer to autoimmune disorders.
Market capitalization of all companies included in a broad market index - GURU.Markets
XORTX Therapeutics develops drugs to treat kidney diseases. Its market capitalization reflects its scientific approach and potential to help patients with kidney failure.
Book value capitalization of the company, segment and market as a whole
XRTX - Book value capitalization of the company XORTX Therapeutics Inc.
XORTX Therapeutics develops drugs to treat kidney diseases. Its book value represents its financial resources for R&D. It consists of cash, which allows the company to conduct clinical trials of its candidates. How has this vital capital changed? The chart below shows.
XRTX - Share of the company's book capitalization XORTX Therapeutics Inc. within the market segment - Pharma immune
XORTX Therapeutics Inc. develops drugs for the treatment of kidney diseases. Its scientific activities require a resource base: a laboratory for developing and testing its therapeutic candidates. The chart shows the company's share of the physical R&D infrastructure in this specific segment.
Market segment balance sheet capitalization - Pharma immune
XORTX is a biopharmaceutical company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. XORTX focuses on drug development, and its capital is its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
XORTX's assets are not factories, but capital allocated to the development of drugs for the treatment of kidney diseases based on the theory of the link between uric acid levels and disease progression. These assets represent the financial resources available to test this scientific hypothesis.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - XORTX Therapeutics Inc.
XORTX Therapeutics is a biopharmaceutical company developing drugs for the treatment of kidney diseases. Its market value is determined by its scientific approach and its lead candidate. This is a bet on success in this complex field of medicine.
Market to book capitalization ratio in a market segment - Pharma immune
XORTX Therapeutics develops drugs to treat kidney disease. Its high valuation on this chart reflects the success of its clinical trials, which, if successful, could unlock a multi-billion dollar market.
Market to book capitalization ratio for the market as a whole
XORTX Therapeutics is working on a treatment for kidney diseases. Like many biotech companies, its market valuation is based on the prospects of its clinical programs. This chart demonstrates how willing investors are to invest in research and development targeting chronic and common diseases.
Debts of the company, segment and market as a whole
XRTX - Company debts XORTX Therapeutics Inc.
XORTX, a clinical-stage biopharmaceutical company developing drugs to treat kidney diseases, is entirely dependent on external funding. This chart illustrates the company's financial needs during the long and risky development of drugs for complex diseases.
Market segment debts - Pharma immune
XORTX Therapeutics is a Canadian biopharmaceutical company developing drugs to treat kidney diseases based on the hypothesis about the role of uric acid. This chart shows how the company is funding its clinical-stage research to test its scientific theory and develop a potential new approach to treating common diseases.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio XORTX Therapeutics Inc.
XORTX Therapeutics is a Canadian pharmaceutical company developing drugs to treat kidney diseases, including those associated with COVID-19. Clinical trials in nephrology are a lengthy and expensive process. This chart shows how the company is using debt to finance its high-risk but potentially important research.
Market segment debt to market segment book capitalization - Pharma immune
XORTX Therapeutics is a biopharmaceutical company developing drugs to treat kidney diseases associated with abnormal uric acid metabolism. This chart shows how the company is funding its clinical trials, comparing its debt structure to the overall financial picture in the biotech sector.
Debt to book value of all companies in the market
XORTX Therapeutics develops drugs to treat kidney disease. Biopharmaceutical research is a marathon, requiring massive financial investments. How dependent is the company on debt financing? This chart, showing the overall level of debt in the economy, provides context for assessing its survival strategy.
P/E of the company, segment and market as a whole
P/E - XORTX Therapeutics Inc.
XORTX Therapeutics is a Canadian biopharmaceutical company developing drugs to treat kidney diseases. This chart shows how investors view its scientific approach. The valuation is volatile and depends on the results of clinical trials and partnerships.
P/E of the market segment - Pharma immune
XORTX Therapeutics is a biopharmaceutical company developing drugs to treat kidney diseases, specifically polycystic kidney disease, by inhibiting xanthine oxidase. This chart illustrates the average valuation in the immunopharmaceutical sector, where investors evaluate new approaches to treating chronic and progressive diseases.
P/E of the market as a whole
XORTX Therapeutics Inc. is a pharmaceutical company focused on developing treatments for kidney diseases, particularly those associated with high uric acid levels. This chart reflects the overall risk appetite of investors in biotech. It helps understand whether XRTX's valuation is based on the potential of its research and development or whether it moves in tandem with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company XORTX Therapeutics Inc.
XORTX Therapeutics is a biopharmaceutical company developing drugs to treat kidney diseases based on abnormal uric acid metabolism. This chart shows how investors view the company's scientific approach and the commercial potential of its developments in treating progressive kidney diseases.
%20P%2FE%20XORTX%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-XORTX-Therapeutics-Inc.&v=1772513768276 "Chart of the company's future (projected) P/E XORTX Therapeutics Inc.")
Future (projected) P/E of the market segment - Pharma immune
XORTX Therapeutics is a biopharmaceutical company developing drugs for the treatment of kidney diseases. Its approach is based on uric acid control. The chart shows the average profitability expectations in the sector. It helps understand the level of investor confidence in this scientific hypothesis and the commercial potential of XORTX's developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772513768280 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
XORTX Therapeutics is a Canadian pharmaceutical company developing drugs to treat kidney diseases. Its approach is based on uric acid control. This chart of overall risk appetite in the biotech sector shows how willing investors are to fund companies with novel scientific approaches to treating common diseases.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513768305 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of kidney diseases, particularly those associated with high uric acid levels. Financial indicators reflect R&D expenses. This chart shows investments in a new approach to treating advanced kidney disease.
Profit of companies in the market segment - Pharma immune
XORTX Therapeutics Inc. is a biopharmaceutical company developing drugs to treat kidney diseases, particularly by lowering uric acid levels. This chart shows overall profitability in the immunopharmaceutical and nephrology sectors, where there is a significant need for new methods to slow the progression of chronic kidney disease.
Overall market profit
XORTX Therapeutics Inc. is a biopharmaceutical company developing drugs to treat kidney diseases. Its prospects depend on the success of clinical trials. The need for treatments for these diseases is independent of economic conditions, making the company's business immune to the cycles observed in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company XORTX Therapeutics Inc.
XORTX Therapeutics is a pharmaceutical company developing drugs to treat kidney diseases, particularly those associated with high uric acid levels. Future profits depend on the success of clinical trials. This chart shows analysts' speculative expectations for its approach to treating progressive kidney disease.
%20profit%20of%20the%20company%20XORTX%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-XORTX-Therapeutics-Inc.&v=1772513768344 "Graph of future (projected) profit of the company XORTX Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Pharma immune
XORTX Therapeutics is a biopharmaceutical company developing treatments for kidney diseases, particularly those associated with elevated uric acid levels. Its approach is aimed at slowing the progression of the disease. This chart shows revenue expectations for the immunopharmaceuticals sector, providing context for evaluating XORTX's strategy.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772513768368 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
XORTX Therapeutics Inc. is a biopharmaceutical company developing drugs to treat kidney diseases. Its future depends on the results of clinical trials. This economic outlook affects investors' overall risk appetite, which is critical for biotech financing.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513768408 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - XORTX Therapeutics Inc.
XORTX Therapeutics is a biopharmaceutical company developing treatments for kidney diseases. It has no revenue at the clinical stage. This chart reflects investor sentiment on its scientific approach to uric acid management and its potential.
P/S market segment - Pharma immune
XORTX Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat kidney diseases, particularly those associated with high uric acid levels. Their approach may offer a new way to slow the progression of kidney failure. This chart reflects the average revenue estimate for the sector, which helps assess the potential of XORTX's developments.
P/S of the market as a whole
XORTX Therapeutics is a pharmaceutical company developing drugs to treat kidney diseases, particularly those associated with abnormally high uric acid levels. This chart illustrates that the valuation of such clinical-stage companies is based on the potential of their developments for large markets, rather than current sales.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company XORTX Therapeutics Inc.
XORTX Therapeutics is a biopharmaceutical company developing treatments for kidney diseases, including those associated with high uric acid levels. Its revenue estimates are important to the company. They reflect investor expectations for the success of its clinical programs and the commercial potential of its drugs for the treatment of progressive kidney disease, a serious problem.
%20P%2FS%20XORTX%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-XORTX-Therapeutics-Inc.&v=1772513768624 "The graph of the company's future (projected) P/S XORTX Therapeutics Inc.")
Future (projected) P/S of the market segment - Pharma immune
XORTX Therapeutics is a biopharmaceutical company developing drugs to treat kidney disease. Its approach is based on lowering uric acid levels. This chart compares the company's estimated future sales with industry expectations. It shows how investors view its scientific hypothesis and the potential of its drugs for treating polycystic kidney disease.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772513768640 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
XORTX Therapeutics develops drugs to treat kidney disease by targeting uric acid metabolism. The company's future depends on the success of its clinical programs. This market forecast chart reflects investor confidence in the significant need for new treatments for chronic kidney disease.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513768690 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales XORTX Therapeutics Inc.
This chart shows the financial performance of XORTX Therapeutics, a clinical-stage biopharmaceutical company developing drugs for the treatment of kidney diseases. Commercial sales revenue is not available, and financial indicators reflect clinical trial expenses.
Sales of companies in the market segment - Pharma immune
XORTX Therapeutics is a Canadian biopharmaceutical company focused on the treatment of kidney diseases. Being in the clinical stage, it does not yet have sales revenue. Its future revenue will depend on the success of its lead candidate, which is aimed at slowing the progression of polycystic kidney disease.
Overall market sales
XORTX Therapeutics Inc. is a biopharmaceutical company developing drugs to treat kidney diseases. Its success depends on the results of clinical trials. This general economics chart is irrelevant for a company working to solve serious medical problems, where demand is driven by patient needs, not financial cycles.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company XORTX Therapeutics Inc.
XORTX Therapeutics is a biopharmaceutical company developing treatments for kidney diseases, particularly those associated with elevated uric acid levels. Future revenues are dependent on the success of clinical trials. This chart reflects analyst expectations for the commercial potential of its approach to treating advanced kidney disease.
%20sales%20of%20the%20company%20XORTX%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-XORTX-Therapeutics-Inc.&v=1772513768966 "Schedule of future (projected) sales of the company XORTX Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Pharma immune
XORTX Therapeutics Inc. develops drugs to treat kidney diseases, particularly those associated with high uric acid levels. This chart shows the outlook for the pharmaceutical market. Is awareness of the link between uric acid and kidney disease growing, creating a new market? This reflects general expectations.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772513768995 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
XORTX Therapeutics is a biopharmaceutical company developing drugs to treat kidney diseases. Its success depends on clinical trial results and regulatory approval. The overall economic trends reflected in this chart do not impact patient demand for innovative treatments for advanced kidney diseases.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513769030 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality XORTX Therapeutics Inc.
XORTX Therapeutics is a biopharmaceutical company developing drugs for the treatment of kidney diseases, particularly those associated with abnormal uric acid metabolism. This chart reflects its financial performance at the clinical trial stage. Profitability depends on the success of its lead candidate and its ability to slow the progression of chronic kidney disease.
Market segment marginality - Pharma immune
XORTX Therapeutics Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of kidney diseases. This chart reflects its financial position, with profitability entirely dependent on future clinical trial success, regulatory approval, and commercialization of its kidney disease treatment approaches.
Market marginality as a whole
XORTX Therapeutics develops drugs for the treatment of kidney diseases. The company operates in an area with a high unmet medical need. Its future depends on the results of clinical trials. This total return chart reflects the investment climate, which determines the availability of capital for biotech companies.
Employees in the company, segment and market as a whole
Number of employees in the company XORTX Therapeutics Inc.
XORTX Therapeutics is a Canadian biopharmaceutical company developing drugs for the treatment of kidney diseases. Its small, largely virtual staff manages clinical trials. This diagram illustrates a lean structure that focuses all resources on advancing its candidates through key stages of clinical development.
Share of the company's employees XORTX Therapeutics Inc. within the market segment - Pharma immune
XORTX Therapeutics is a biopharmaceutical company developing drugs to treat kidney diseases associated with high uric acid levels. Its primary focus is clinical research. This chart shows the company's market share in the biotech industry, reflecting the scale of its clinical programs and the size of its research team.
Number of employees in the market segment - Pharma immune
XORTX Therapeutics is a biopharmaceutical company developing drugs to treat kidney disease by lowering uric acid levels. The chart shows the company's presence in the immunopharmaceutical sector. XORTX's approach is based on the growing understanding of the role of uric acid in the progression of kidney disease.
Number of employees in the market as a whole
XORTX Therapeutics is a pharmaceutical company developing drugs for the treatment of kidney diseases. Its development depends on the results of clinical trials. Unlike the broader labor market reflected in this chart, hiring at XORTX is a targeted investment in science, where every specialist contributes to the fight against chronic diseases.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company XORTX Therapeutics Inc. (XRTX)
XORTX Therapeutics is a biotech company focused on treating kidney disease by modulating uric acid levels. This chart shows how the market values their R&D. It reflects the market value per employee, which is a measure of the value of their pipeline and their scientific approach to treating kidney disease.
%20of%20the%20company%20XORTX%20Therapeutics%20Inc.%20(XRTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-XORTX-Therapeutics-Inc.-XRTX&v=1772513769204 "Chart of market capitalization per employee (in thousands of dollars) of the company XORTX Therapeutics Inc. (XRTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
XORTX Therapeutics (XRTX) is a biopharmaceutical company developing drugs for the treatment of kidney diseases. In this area, this metric reflects the potential of their key candidate. A high value per employee may indicate that their approach to lowering uric acid levels could slow the progression of chronic kidney disease.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772513769228 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
XORTX Therapeutics is a biopharmaceutical company developing treatments for kidney diseases. Its value, like that of other clinical-stage biotechs, is driven by research results. The chart shows a high valuation per employee, as its market cap reflects investors' expectations for the future success of its innovative approaches.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513769243 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company XORTX Therapeutics Inc. (XRTX)
XORTX Therapeutics is a clinical-stage biotech company developing drugs for kidney disease. This chart reflects its R&D workload. A negative R&D workload (loss per employee) is typical for biotech companies, reflecting the amount of capital invested in each scientist to conduct clinical trials.
%20Chart%20XORTX%20Therapeutics%20Inc.%20(XRTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-XORTX-Therapeutics-Inc.-XRTX&v=1772513769248 "Company Profit Per Employee (in thousands of dollars) Chart XORTX Therapeutics Inc. (XRTX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
XORTX Therapeutics Inc. is a Canadian biopharmaceutical company focused on treating kidney diseases. In this field, efficiency per employee is critical for drug development. The graph shows the financial return on investment for a small but specialized team, which is an indicator of the potential of their developments for patients.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772513769266 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
XORTX Therapeutics is a Canadian biotech company focused on treating kidney diseases. They repurpose existing drugs for new purposes. This is an R&D business. This chart, showing average market profitability, demonstrates how the biotech model, with its small workforce and high stakes, differs from the rest of the economy.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513769315 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee XORTX Therapeutics Inc. (XRTX)
XORTX Therapeutics is a biopharmaceutical company developing drugs for kidney disease. At the clinical stage, revenue per employee can be zero. This graph represents future potential: a successful drug for such a large market could generate very high revenue per team member.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-XORTX-Therapeutics-Inc.-XRTX&v=1772513769355 "Sales chart per company employee XORTX Therapeutics Inc. (XRTX)")
Sales per employee in the market segment - Pharma immune
XORTX Therapeutics (XRTX) is a Canadian clinical-stage biotech focused on treating kidney disease, specifically by lowering uric acid levels. They have no commercial revenue. This chart, showing the average revenue in the sector, serves as a barometer of XORTX's R&D staffing costs.
Sales per employee for the market as a whole
XORTX Therapeutics is a biotech company focused on treating kidney disease by modulating uric acid levels. Currently, their business is focused on R&D. This chart reflects their clinical stage: the company is investing in research and has no commercial revenue yet.
Short shares by company, segment and market as a whole
Shares shorted by company XORTX Therapeutics Inc. (XRTX)
XORTX (XRTX) is a biotech company repurposing existing kidney disease drugs. This chart shows the number of short positions. The short positions may reflect skepticism that the old drugs will be effective for new, complex indications.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-XORTX-Therapeutics-Inc.-XRTX&v=1772513769466 "Short Shares Chart for the Company XORTX Therapeutics Inc. (XRTX)")
Shares shorted by market segment - Pharma immune
XORTX Therapeutics (XRTX) is a pharmaceutical company specializing in the treatment of kidney disease by lowering uric acid levels. This chart aggregates short positions in the biotech (nephrology) sector. It reflects investor concerns about the risks of clinical trials in this complex therapeutic area.
Shares shorted by the overall market
XORTX is a biotech focused on kidney disease. This chart shows the overall market pessimism. For an R&D company without revenue, this is a dangerous time. Investors fear running out of cash for research, and raising a new round in this "fear market" will be impossible.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator XORTX Therapeutics Inc. (XRTX)
XORTX Therapeutics repurposes established drugs (for example, for gout) to treat rare kidney diseases. This is R&D with lower risks. This graph measures the "temperature" of this R&D. It "heats up" when the company receives approval for new phases of trials or presents strong data.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-XORTX-Therapeutics-Inc.-XRTX&v=1772513769555 "RSI 14 indicator chart for the company's stock XORTX Therapeutics Inc. (XRTX)")
RSI 14 Market Segment - Pharma immune
XORTX (XRTX) is a biotech company focused on treating kidney disease. They repurpose established kidney-protective drugs for various conditions. This chart tracks overall sentiment in the Pharma/Immunology sector. It helps investors understand whether XRTX's performance reflects their niche or whether the entire biotech sector is overheated or oversold.
RSI 14 for the overall market
For XORTX (XRTX), a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the money supply is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast XRTX (XORTX Therapeutics Inc.)
XORTX Therapeutics is a biotech company developing drugs (xanthine oxidase inhibitors) for the treatment of kidney diseases, specifically autosomal dominant polycystic kidney disease. This chart shows the speculative average 12-month price target from analysts based on their assessment of the company's R&D portfolio.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-XRTX-XORTX-Therapeutics-Inc.&v=1772513769641 "A chart showing analyst consensus forecasts for the expected stock price. XRTX (XORTX Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price XRTX (XORTX Therapeutics Inc.)
XORTX is a Canadian biotech company developing drugs (inhibitors) for the treatment of kidney diseases, particularly polycystic kidney disease (ADPKD). This chart shows the difference between the market valuation and the consensus estimate. It illustrates the potential experts see in their R&D portfolio and the chances of clinical success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-XRTX-XORTX-Therapeutics-Inc.&v=1772513769673 "A chart showing the difference between the consensus forecast and the actual stock price. XRTX (XORTX Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
XORTX is a biotech company developing drugs (xanthine oxidase inhibitors) for the treatment of severe kidney diseases. This is risky R&D. This chart reflects analysts' overall expectations for the entire "immune" (and kidney) pharmaceutical sector. It shows whether experts believe a breakthrough in kidney disease treatment is possible.
Analysts' consensus forecast for the overall market share price
XORTX Therapeutics is a biotech company specializing in developing drugs to treat kidney diseases. This chart shows the overall market "risk appetite." For XORTX, a high-risk clinical-stage company, overall market optimism (an upward trend in the chart) is critical for raising capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index XORTX Therapeutics Inc.
XORTX is a kidney-focused biotech company. Their specialty is xanthine inhibitors: they repurpose old gout drugs to (they claim) protect kidneys in polycystic kidney disease (PKD) and diabetes. This chart is a pure indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data.
AKIMA Market Segment Index - Pharma immune
XORTX Therapeutics is a biopharmaceutical company focused on treating kidney diseases, particularly those associated with abnormal uric acid metabolism. Their goal is to address the cause, not the symptom. This chart compares their composite index to their sector, demonstrating how their focused approach stands out from other immunology companies.
The AKIM Index for the overall market
XORTX Therapeutics is a biopharmaceutical company developing treatments for progressive kidney disease (polycystic kidney disease). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this Canadian research company stacks up against the broader economic trends affecting nephrology.
